1215197-17-3

Basic information

• Product Name: (5S)-5-{[((E)-4-chlorobenzylidene)amino]methyl}-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-1,3-oxazolidin-2-one
• Synonyms: (5S)-5-{[((E)-4-chlorobenzylidene)amino]methyl}-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-1,3-oxazolidin-2-one
• CAS NO: 1215197-17-3
• Molecular Weight: 433.934
• Mol File: 1215197-17-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (5S)-5-{[((E)-4-chlorobenzylidene)amino]methyl}-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-1,3-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (5S)-5-{[((E)-4-chlorobenzylidene)amino]methyl}-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-1,3-oxazolidin-2-one(1215197-17-3)
• EPA Substance Registry System: (5S)-5-{[((E)-4-chlorobenzylidene)amino]methyl}-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-1,3-oxazolidin-2-one(1215197-17-3)

Safety Data

• Hazardous Substances Data: 1215197-17-3(Hazardous Substances Data)

Upstream product

• 1634-04-4 tert-butyl methyl ether 
• 1907-33-1 lithium tert-butoxide 
• 104-88-1 4-chlorobenzaldehyde 
• 168828-71-5 [3-fluoro-4-(4-thiomorpholinyl)phenyl]carbamic acid, phenylmethyl ester 

Downstream Products

• 24665-93-8 2-Imino-1,3-oxazolidin 

Relevant articles and documents

Combination Therapy for Tuberculosis

The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering